HIV-2 infection: A call for controlled trials

AIDS

Volumn 22, Issue 16, 2008, Pages 2073-2074

  Matheron, Sophie ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Antiretroviral therapy; HIV 2; HIV 2 RNA quantification; International collaboration; Randomized controlled trial; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AFRICA; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; NONHUMAN; NOTE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

EID: 55249091640     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830edd59     Document Type: Note

References (3)

1. Gottlieb GS, Eholié S, Nkengasong J, Jallow S, Rowland-Jones S, Whittle HC, Sow PS. OPINION PIECE: a call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS 2008; 22:000-000.
2. Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 2008; 22:457-468.
3. Damond F, Benard A, Ruelle J, Alabi A, Kupfer B, Gomes P, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008; 46:2088-2091.